cyclophosphamide or azathioprine

Phase 3Small molecule

cyclophosphamide or azathioprine is one of 53 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Lupus NephritisActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Lupus NephritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Halaven

Eisai

Preclinical

38 3

cyclophosphamide or azathioprine

SSun Yat-sen University

Phase 3

1 4

MS Contin

Merck & Co.

Preclinical

2 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Completed·SSun Yat-sen University··NCT06373744·597 enrolled

Lupus Nephritis1 trial

Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis

Completed·SSun Yat-sen University·Phase 3·NCT00615173·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for cyclophosphamide or azathioprine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cyclophosphamide or azathioprine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cyclophosphamide or azathioprine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

cyclophosphamide or azathioprine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Lupus Nephritis1 trial

References

Drug Info

Quick Facts

Related News